Patrik Brundin
Brundin, Patrik, 1961-
Brundin, Patrik
VIAF ID: 17191266 (Personal)
Permalink: http://viaf.org/viaf/17191266
Preferred Forms
- 100 1 _ ‡a Brundin, Patrik
-
-
- 100 1 _ ‡a Brundin, Patrik
-
-
- 100 1 _ ‡a Brundin, Patrik ‡d 1961-
- 100 1 _ ‡a Brundin, Patrik, ‡d 1961-
- 100 0 _ ‡a Patrik Brundin
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Failure of transdifferentiation of adult hematopoietic stem cells into neurons. | |
Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival | |
Free radicals and ailing proteins--the culprits behind Parkinson disease? | |
Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice | |
GDNF treatment in Parkinson's disease: time for controlled clinical trials? | |
Growth factors and feeder cells promote differentiation of human embryonic stem cells into dopaminergic neurons: a novel role for fibroblast growth factor-20 | |
Gut feelings about smoking and coffee in Parkinson's disease | |
Harnessing endogenous stem cells to treat neurodegenerative disorders of the basal ganglia | |
How strong is the evidence that Parkinson's disease is a prion disorder? | |
Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease | |
Huntington's disease: a synaptopathy? | |
Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation | |
Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease | |
Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor | |
Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease | |
Induction of dopaminergic neurons from growth factor expanded neural stem/progenitor cell cultures derived from human first trimester forebrain. | |
Involvement of Ngn2, Tbr and NeuroD proteins during postnatal olfactory bulb neurogenesis | |
Islet beta-cell area and hormone expression are unaltered in Huntington's disease | |
Journal of Parkinson's Disease--an excellent first year and a new sister | |
Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes | |
Lesion of the subiculum reduces the spread of amyloid beta pathology to interconnected brain regions in a mouse model of Alzheimer's disease | |
Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports | |
Membrane interaction of α-synuclein in different aggregation states | |
Microchannel acoustophoresis does not impact survival or function of microglia, leukocytes or tumor cells | |
Midbrain expression of Delta-like 1 homologue is regulated by GDNF and is associated with dopaminergic differentiation | |
Mind the gut: secretion of α-synuclein by enteric neurons | |
Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. | |
Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion | |
Neural grafting in Parkinson's disease Problems and possibilities | |
Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease. | |
Neurogenin2 directs granule neuroblast production and amplification while NeuroD1 specifies neuronal fate during hippocampal neurogenesis | |
Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells | |
Nilotinib - Differentiating the Hope from the Hype | |
No evidence for new dopaminergic neurons in the adult mammalian substantia nigra | |
Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease | |
Novel animal model defines genetic contributions for neuron-to-neuron transfer of α-synuclein | |
The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases | |
On the move to stimulate cell plasticity in the substantia nigra in Parkinson's disease | |
The Origin, Development and Molecular Diversity of Rodent Olfactory Bulb Glutamatergic Neurons Distinguished by Expression of Transcription Factor NeuroD1 | |
Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression | |
Oxidative stress in neurodegenerative disease: causation or association? | |
Parkinson Matters | |
Precision medicine for disease modification in Parkinson disease | |
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease | |
Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease | |
Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. | |
Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice | |
Reduced neurogenesis in the rat hippocampus following high fructose consumption | |
Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease | |
Research in motion: the enigma of Parkinson's disease pathology spread | |
Restorative therapies in Parkinson's disease, c2006: | |
Rozpoznawanie i leczenie otępienia z ciałami Lewy'ego : czwarte stanowisko DLB Consortium = Diagnosis and management of dementia with Lewy bodies : fourth consensus report of the DLB Consortium | |
Rozpoznawanie i leczenie otępienia z ciałami Lewy'ego / Ian G. McKeith [i inni] // MP Medycna Praktyczna. Neurologia. - 5 (47) 2017, strony 21-39. | |
Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. | |
Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. | |
Silencing synuclein at the synapse with PLK2 | |
Solving the conundrum of insoluble protein aggregates. | |
Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology | |
Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term. | |
Stage-specific modulation of cortical neuronal development by Mmu-miR-134. | |
Stem cell therapy for Parkinson's disease: where do we stand? | |
Stem cells: hype or hope? | |
Stromal cell-derived inducing activity does not promote dopaminergic differentiation, but enhances differentiation and proliferation of neural stem cell-derived astrocytes | |
Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. | |
Therapeutic approaches to target alpha-synuclein pathology. | |
The Times They Are a-Changin': Parkinson's Disease 20 Years from Now | |
Towards a transplantation therapy for Parkinson's disease : an experimental study on intracerebral grafts of fetal dopamine neurons | |
Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice | |
Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line--studies in vitro and after intracerebral grafting in vivo | |
The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. | |
Ultrastructural characterization of dissociated embryonic ventral mesencephalic tissue treated with neuroprotectants. | |
The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies | |
What's to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease? | |
α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells | |
α-Synuclein: the long distance runner |